The integration of artificial intelligence (AI) with organoid-based drug testing platforms offers unprecedented opportunities for high-content, high-throughput phenotypic analysis in bladder cancer research. Current manual organoid assessment methods are subjective, low-throughput, and insufficiently sensitive for detecting subtle morphological responses to therapeutic agents. This study reviews the current state of AI-assisted organoid analysis, proposes a structured computational pipeline for bladder cancer organoid phenotyping, and evaluates the translational readiness of AI-organoid platforms for clinical deployment. We discuss that AI-assisted phenotyping will not merely accelerate data acquisition but also fundamentally expand the biological information extractable from organoid assays, enabling the identification of novel drug response biomarkers that remain imperceptible to human observers. Multicenter validation, regulatory engagement, and deliberate human-AI workflow integration are essential prerequisites before these platforms can be responsibly deployed in clinical settings.
References
[1] Roviello, G., Santoni, M., Sonpavde, G. P., Catalano, M. (2024) The evolving treatment landscape of metastatic urothelial cancer. Nature Reviews Urology, 21, 580-592.
[2] Way, G. P., Sailem, H., Shave, S., Kasprowicz, R., Carragher, N. O. (2023) Evolution and impact of high content imaging. SLAS Discovery, 28(7), 292-305.
[3] Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Valeri, N. (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), 920-926.
[4] Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Voest, E. E. (2019) Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 11(513), eaay2574.
[5] Greenhalgh, T., Wherton, J., Papoutsi, C., Lynch, J., Hughes, G., Hinder, S., Shaw, S. (2017) Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. Journal of Medical Internet Research, 19(11), e8775.
[6] Harris, A. L. (2002) Hypoxia – a key regulatory factor in tumour growth. Nature Reviews Cancer, 2(1), 38-47.
[7] Andrews, P. W., Barbaric, I., Benvenisty, N., Draper, J. S., Ludwig, T., Merkle, F. T., Pera, M. F. (2022) The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells. Cell Stem Cell, 29(12), 1624-1636.
[8] Beghin, A., Grenci, G., Sahni, G., Guo, S., Rajendiran, H., Delaire, T., Viasnoff, V. (2022) Automated high-speed 3D imaging of organoid cultures with multi-scale phenotypic quantification. Nature Methods, 19(7), 881-892.
[9] Yannas, I. V. (2015) Tissue and organ regeneration in adults: extension of the paradigm to several organs (2nd ed.). Springer New York.
[10] Drost, J., Clevers, H. (2018) Organoids in cancer research. Nature Reviews Cancer, 18(7), 407-418.
[11] Ioannidis, J. P. (2005) Why most published research findings are false. PLoS Medicine, 2(8), e124.
[12] Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Doll, R. (1988) Randomised trial of prophylactic daily aspirin in British male doctors. British Medical Journal (Clinical Research Edition), 296(6618), 313-316.
Share and Cite
Peng, H., Shang, J., Qian, K., Zou, C., Shi, J., Zhou, Z., Xiang, W., Xu, Z., Cao, X., Wang, G. (2026) Artificial Intelligence-Assisted Phenotypic Analysis of Bladder Cancer Organoids: Toward Digital Precision Oncology. Scientific Research Bulletin, 3(1), 34-41. https://doi.org/10.71052/srb2024/GOUI6134